IndexIQ Advisors
ATRA icon

IndexIQ Advisors’s Atara Biotherapeutics ATRA Stock Holding History

IndexIQ Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,742
Closed -$1.24M – 562
2017
Q4 		$1.24M Buy
2,742
+1,055
+63% +$390K 0.05% 338
2017
Q3 		$698K Buy
1,687
+765
+83% +$288K 0.03% 395
2017
Q2 		$323K Buy
+922
New +$355K 0.02% 449

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IndexIQ Advisors's ATRA Position: Q1 2018 in Review

IndexIQ Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2018, closing a stake of 2,742 shares — an estimated $1.24M sold.

IndexIQ Advisors first reported a position in ATRA in Q2 2017 and held it in 3 quarters. The position peaked at $1.24M in Q4 2017. 114 funds tracked by Wall St. Rank hold ATRA as of Q1 2018.

  • IndexIQ Advisors reported no remaining Atara Biotherapeutics position as of Q1 2018 after selling out during the quarter.
  • IndexIQ Advisors sold 2,742 Atara Biotherapeutics shares in Q1 2018, an estimated $1.24M.
  • IndexIQ Advisors first reported a position in Atara Biotherapeutics in Q2 2017 and held it in 3 quarters.
  • IndexIQ Advisors's Atara Biotherapeutics position peaked at $1.24M in Q4 2017.
  • 114 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2018.

Based on IndexIQ Advisors's 13F filing for Q1 2018, filed 15 May 2018.